Weekly Respiratory Research Analysis
This week’s respiratory literature highlights three high-impact advances: a randomized trial follow-up (FIBRONEER-ILD) showing nerandomilast reduced clinically important outcomes including the composite of acute exacerbation, respiratory hospitalization, and death in progressive pulmonary fibrosis; a large pragmatic phase 3 ED trial (PRONTO) demonstrating that adding rapid procalcitonin testing to NEWS2-based care reduced 28-day mortality in suspected sepsis; and a multicenter prospective study
Summary
This week’s respiratory literature highlights three high-impact advances: a randomized trial follow-up (FIBRONEER-ILD) showing nerandomilast reduced clinically important outcomes including the composite of acute exacerbation, respiratory hospitalization, and death in progressive pulmonary fibrosis; a large pragmatic phase 3 ED trial (PRONTO) demonstrating that adding rapid procalcitonin testing to NEWS2-based care reduced 28-day mortality in suspected sepsis; and a multicenter prospective study (PHIND) showing feasible, near-patient IL-6/sTNFR1 bedside assays can rapidly subtype ARDS with large prognostic separation. Collectively these studies push antifibrotic therapeutics, rapid biomarker-guided pathways, and bedside precision phenotyping toward practice impact.
Selected Articles
1. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
In 1,176 patients with progressive pulmonary fibrosis and mean 17 months observation, nerandomilast reduced the composite risk of first acute ILD exacerbation, respiratory hospitalization, or death (HRs ~0.77–0.78 versus placebo) with a favorable tolerability profile; benefits were larger in patients not on background nintedanib.
Impact: Provides large randomized, extended-follow-up evidence that an antifibrotic agent reduces clinically important events including death in progressive pulmonary fibrosis — a potential practice-changing disease-modifying therapy.
Clinical Implications: Consider nerandomilast as a disease-modifying option in progressive pulmonary fibrosis, particularly in patients not receiving background nintedanib; integrate monitoring for event reduction and long-term safety in practice.
Key Findings
- Nerandomilast reduced the composite of first AE-ILD, respiratory hospitalization, or death (HR 0.78 for 9 mg bid; HR 0.77 for 18 mg bid vs placebo).
- Greater benefit observed in patients not taking background nintedanib (HR 0.69 and 0.65 for 9 mg and 18 mg).
- Favorable safety and tolerability over mean 15.1 months on study drug and 17.0 months observation.
2. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
In a pragmatic multicenter phase 3 trial (>7,600 randomized; 5,453 analyzed for co-primary endpoints), adding rapid procalcitonin testing to NEWS2-based emergency care did not change 3-hour IV antibiotic initiation but significantly reduced 28-day mortality (13.6% vs 16.6%; adjusted risk difference −3.12 percentage points), meeting non-inferiority and superiority criteria without increasing adverse events.
Impact: A large pragmatic randomized trial demonstrating that a rapid biomarker (PCT) added to routine ED evaluation improves survival in suspected sepsis — high immediate implementation relevance for ED pathways.
Clinical Implications: Emergency departments should evaluate integrating rapid procalcitonin into NEWS2-based pathways with attention to workflow, clinician adherence, and monitoring of stewardship and outcome metrics; the approach may reduce sepsis mortality without increasing early antibiotic exposure.
Key Findings
- 3-hour IV antibiotic initiation was similar between groups (~48%).
- 28-day mortality lower with procalcitonin-guided care (13.6% vs 16.6%; adjusted risk difference −3.12 percentage points).
- Clinicians considered the procalcitonin result in approximately two-thirds of guided-care decisions; adverse events were comparable.
3. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
In a prospective multicentre ICU cohort (n=512 phenotyped), a near-patient benchtop immunoanalyser measuring IL-6 and sTNFR1, combined with bicarbonate and a parsimonious model, classified ARDS/AHRF into hyperinflammatory (~18%) and hypoinflammatory groups within ~1 hour. Hyperinflammatory patients had markedly higher 60-day mortality (51% vs 28%; adjusted OR 2.7), demonstrating feasibility and strong prognostic separation for bedside phenotyping.
Impact: First large prospective implementation of near-patient ARDS subphenotyping with clear prognostic separation—provides an actionable tool for phenotype-stratified trials and ICU decision-making.
Clinical Implications: ICUs can feasibly deploy rapid IL-6/sTNFR1 testing to stratify ARDS patients for prognosis and trial enrollment; hyperinflammatory patients may be prioritized for immunomodulatory strategies in future phenotype-directed trials.
Key Findings
- Near-patient IL-6/sTNFR1 + bicarbonate testing classified ARDS/AHRF into hyper- and hypoinflammatory phenotypes prospectively.
- Hyperinflammatory phenotype had higher 60-day mortality (51% vs 28%; adjusted OR 2.7).
- Feasibility demonstrated across multiple centers with ~1-hour assay turnaround enabling bedside actionability.